V116 shows safety and immunogenicity in high-risk children for pneumococcal disease

The successful phase 3 trial of V116 demonstrates its potential to become a preferred pneumococcal vaccination option for high-risk children, which could significantly alter vaccination practices. This shift may lead to increased market share for V116 at the expense of existing vaccines like PPSV23, necessitating close monitoring of regulatory developments and guideline updates.

The successful phase 3 trial of V116 demonstrates its potential to become a preferred pneumococcal vaccination option for high-risk children, which could significantly alter vaccination practices. This shift may lead to increased market share for V116 at the expense of existing vaccines like PPSV23, necessitating close monitoring of regulatory developments and guideline updates.

Trial Update

The phase 3 study demonstrated that V116 met noninferiority and superiority criteria for immunogenicity compared to PPSV23 in children with chronic conditions.

The successful phase 3 trial of V116 demonstrates its potential to become a preferred pneumococcal vaccination option for high-risk children, which could significantly alter vaccination practices. This shift may lead to increased market share for V116 at the expense of existing vaccines like PPSV23, necessitating close monitoring of regulatory developments and guideline updates.

Monitor regulatory approval timelines and potential adoption in vaccination guidelines for high-risk pediatric populations.